Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.47 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | AGXT | P21549 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230078 | 0.98 | L3MBTL1 (0.54) | TSHRMAOATDP1L3MBTL1SSTR1 | |
| SCHEMBL15923248 | 0.98 | L3MBTL1 (0.54) | TSHRMAOATDP1L3MBTL1SSTR1 | |
| SCHEMBL8893085 | 0.98 | L3MBTL1 (0.54) | TSHRMAOATDP1L3MBTL1SSTR1 | |
| SCHEMBL6268086 | 0.98 | L3MBTL1 (0.54) | TSHRMAOATDP1L3MBTL1SSTR1 | |
| Hydrochloric Acid SCHEMBL9781752 | 0.96 | L3MBTL1 (0.53) | TSHRMAOATDP1L3MBTL1SSTR1 | |
| Hydrochloric Acid SCHEMBL20492261 | 0.96 | L3MBTL1 (0.53) | TSHRMAOATDP1L3MBTL1SSTR1 | |
| SCHEMBL26813047 | 0.94 | TSHR (0.54) | TSHRMAOATDP1L3MBTL1SSTR1 | |
| SCHEMBL2782 | 0.94 | TSHR (0.58) | TSHRMAOATDP1L3MBTL1IDO1 | |
| SCHEMBL1568954 | 0.90 | TSHR (0.50) | TSHRMAOATDP1L3MBTL1SSTR1 | |
| SCHEMBL27375031 | 0.90 | TSHR (0.54) | TSHRMAOATDP1L3MBTL1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608810-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-119325378-A | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof | 柯巴斯医药有限公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2024091498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | SEPTERNA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230121302-A1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | VERSITECH LIMITED (CN) | 2023-04-20 | — | — | US | disclosed |
| CN-111410663-B | Preparation of double-target point synergistic compound and application of compound in field of diseases related to multiple myeloma | 北京桦冠医药科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| EP-3052134-B1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-111410663-A | Preparation of double-target point synergistic compound and application of compound in field of diseases related to multiple myeloma | 北京桦冠医药科技有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-105792852-B | Glucose-responsive insulin conjugates | 默沙东公司 | 2019-12-10 | — | — | CN | disclosed |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3280450-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| WO-2008065500-A2 | HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-6344473-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | G.D. SEARLE & CO. | 2002-02-05 | — | — | US | disclosed |
| US-6136829-A | NITRIC OXIDE SYNTHETASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-10-24 | — | — | US | disclosed |
| EP-1000041-A1 | 1,3-DIAZA- HETEROCYCLES AND THEIR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-05-17 | — | — | EP | disclosed |
| US-5981556-A | USEFUL IN TREATMENT OF INFLAMMATORY CONDITIONS AFFECTING THE JOINTS, FOR EXAMPLE ARTHRITIS, AND ALSO INFLAMMATORY BOWEL DISEASE, CARDIVASCULAR ISCHEMIA, DIABETES, CONGESTIVE HEART FAILURE, MYOCARDITIS, ATHEROSCLEROSIS, MIGRAINE | G.D. SEARLE & CO. (US) | 1999-11-09 | — | — | US | disclosed |
| US-5958958-A | ANTIINFLAMMATORY AGENT; HYPOTENSIVE AGENT | G.D. SEARLE & CO. (US) | 1999-09-28 | — | — | US | disclosed |
| WO-1999005131-A1 | 1,3-DIAZA- HETEROCYCLES AND THEIR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-02-04 | — | — | WO | disclosed |
| US-5583259-A | FOR RESOLVING RACEMIC MIXTURES | LES LABORATOIRES BEECHAM S.A. (FR) | 1996-12-10 | — | — | US | disclosed |
| EP-0570443-B1 | AMINOALCOHOLS USEFUL AS OPTICAL RESOLVING AGENTS | SMITHKLINE BEECHAM LAB (FR) | 1995-11-29 | — | — | EP | disclosed |
| US-4592973-A | Hydrophobic microporous membrane | CASTLE TECHNOLOGY CORP. (US) | 1986-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | TSHR 281/4885MAOA 3545/4885TDP1 4593/4885 |
| US-20230121302-A1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | FTH1, FECH, HCCS | TSHR 1353/4885MAOA 45/4885TDP1 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.